Literature DB >> 12906262

Signal transduction via MHC class I molecules in endothelial and smooth muscle cells.

Elaine F Reed1.   

Abstract

MHC class I molecules have long been recognized for their ability to stimulate intracellular signals in T and B lymphocytes. More recently, it has become clear that MHC class I molecules can also initiate intracellular signals in endothelial and smooth muscle cells, which synergize with growth factor receptors to elicit cell proliferation. This review describes our current knowledge of class I-mediated signaling pathways in human endothelial and smooth muscle cells. The role of the class I signaling pathway in modulating cell growth and the clinical significance of this pathway in chronic allograft rejection are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906262     DOI: 10.1615/critrevimmunol.v23.i12.60

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  9 in total

Review 1.  Immunogenicity and allogenicity: a challenge of stem cell therapy.

Authors:  Dominique Charron; Caroline Suberbielle-Boissel; Reem Al-Daccak
Journal:  J Cardiovasc Transl Res       Date:  2008-09-26       Impact factor: 4.132

2.  Evidence for CD16a-Mediated NK Cell Stimulation in Antibody-Mediated Kidney Transplant Rejection.

Authors:  Michael D Parkes; Philip F Halloran; Luis G Hidalgo
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

3.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

4.  Report from a consensus conference on the sensitized patient awaiting heart transplantation.

Authors:  Jon Kobashigawa; Mandeep Mehra; Lori West; Ronald Kerman; James George; Marlene Rose; Adriana Zeevi; Nancy Reinsmoen; Jignesh Patel; Elaine F Reed
Journal:  J Heart Lung Transplant       Date:  2009-03       Impact factor: 10.247

5.  Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts.

Authors:  Peter T Jindra; Aileen Hsueh; Longshen Hong; David Gjertson; Xiu-Da Shen; Feng Gao; Julie Dang; Paul S Mischel; William M Baldwin; Michael C Fishbein; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

6.  Preservation of microvascular barrier function requires CD31 receptor-induced metabolic reprogramming.

Authors:  Kenneth C P Cheung; Silvia Fanti; Egle Solito; Federica M Marelli-Berg; Claudio Mauro; Guosu Wang; Anitha S Nair; Hongmei Fu; Silvia Angeletti; Silvia Spoto; Marta Fogolari; Francesco Romano; Dunja Aksentijevic; Weiwei Liu; Baiying Li; Lixin Cheng; Liwen Jiang; Juho Vuononvirta; Thanushiyan R Poobalasingam; David M Smith; Massimo Ciccozzi
Journal:  Nat Commun       Date:  2020-07-17       Impact factor: 14.919

7.  Monomeric C-reactive protein via endothelial CD31 for neurovascular inflammation in an ApoE genotype-dependent pattern: A risk factor for Alzheimer's disease?

Authors:  Zhengrong Zhang; Hana Na; Qini Gan; Qiushan Tao; Yuriy Alekseyev; Junming Hu; Zili Yan; Jack B Yang; Hua Tian; Shenyu Zhu; Qiang Li; Ibraheem M Rajab; Jan Krizysztof Blusztajn; Benjamin Wolozin; Andrew Emili; Xiaoling Zhang; Thor Stein; Lawrence A Potempa; Wei Qiao Qiu
Journal:  Aging Cell       Date:  2021-10-23       Impact factor: 9.304

8.  Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes.

Authors:  Paul R Moody; Edward J Sayers; Johannes P Magnusson; Cameron Alexander; Paola Borri; Peter Watson; Arwyn T Jones
Journal:  Mol Ther       Date:  2015-09-28       Impact factor: 11.454

9.  MHC Class I Molecules Exacerbate Viral Infection by Disrupting Type I Interferon Signaling.

Authors:  Simo Xia; Yijie Tao; Likun Cui; Yizhi Yu; Sheng Xu
Journal:  J Immunol Res       Date:  2019-09-09       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.